Nanoparticle technology for the delivery of poorly water-soluble drugs

Pharmaceutical Technology

Volumn 30, Issue 2, 2006, Pages 82-92

  Kharb, Vivek ^a   Bhatia, Meenakshi ^a   Dureja, Harish ^a   Kaushik, Deepak ^a  

^a MAHARSHI DAYANAND UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DOSAGE; DRUG PRODUCTS; NANOSTRUCTURED MATERIALS; SOLUBILITY;

COMMERCIAL NANOPARTICLE TECHNOLOGIES; WATER-SOLUBLE DRUGS;

BIOMEDICAL ENGINEERING;

ALCOHOL; AMPHOTERICIN B; ANTIFUNGAL AGENT; ANTILEISHMANIAL AGENT; ANTINEOPLASTIC AGENT; ATOVAQUONE; CREMOPHOR; DANAZOL; MITOTANE; NANOCRYSTAL; NANOPARTICLE; NAPROXEN; NIFEDIPINE; PACLITAXEL; SOLVENT;

AQUEOUS SOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; EVAPORATION; HIGH THROUGHPUT SCREENING; HYDRODYNAMICS; LEISHMANIASIS; MYCOSIS; NANOTECHNOLOGY; PHARMACEUTICAL ENGINEERING; PRECIPITATION; PROCESS DESIGN; REVIEW; SUSPENSION; TABLET FORMULATION;

EID: 33646671464     PISSN: 15432521     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. C. Lipinski, "Poor Aqueous Solubility: An Industry Wide Problem in Drug Discovery," Am. Pharm. Rev. 5, 82-85 (2002).
2. M. Radtke, "Pure Drug Nanoparticles for the Formulation of Poorly Soluble Drugs," New Drugs 3, 62-68 (2001).
3. Y. Ran, A. Jain, and S.H. Yalkowsky, "Solubilization and Preformulation Studies on PG-300995 (an anti-HIV drug)," J. Pharm. Sci. 94 (2), 297-303 (2005).
4. F.A.A. Nunez and S.H. Yalkowsky, "Solubilization of Diazepam," J. Pharm. Sci. Technol. 52 (1), 33-36 (1998).
5. S.K. Han, G.Y. Kim, and Y.H. Park, "Solubilization of Biphenyl Dimethyl Dicarboxylate by Cosolvency," Drug Dev. Ind. Pharm. 25 (11), 1193-1197 (1999).
6. T. Loftsson and M.E. Brewster, "Pharmaceutical Application of Cyclodextrins," J. Pharm. Sci. 85 (10), 1017-1025 (1996).
7. R.K. Chang and A.H. Shojaei, "Effect of Hydroxypropyl Beta-Cyclodextrin on Drug Solubility in Water-Propylene Glycol Mixtures," Drug Dev. Ind. Pharm. 30 (3), 297-302 (2004).
8. A.T. Serajuddin, "Solid Dispersion of Poorly Water-Soluble Drugs: Early Promise, Subsequent Problems, and Recent Breakthroughs," J. Pharm. Sci. 88 (10), 1058-1066 (1999).
9. C. Leuner and J. Dressman, "Improving Drug Solubility for Oral Delivery Using Solid Dispersions," Eur. J. Pharm. BioPharm. 50 (1), 47-60 (2000).
10. J. Breitenbach, "Melt Extrusion: From Process to Drug Delivery Technology," Eur. J. Pharm. BioPharm. 54 (2), 107-117 (2002).
11. R.H. Muller and B.H.L. Bohm, "Nanosuspensions," in Emulsions & Nanosuspensions For the Formulation of Poorly Soluble Drugs, R.H. Muller, S. Bentia, and B.H.L. Bohm, Eds. (Medpharm Scientific Publishers, Stuttgart, Germany, 1998), pp. 149-174.
12. R.H. Muller, C. Jacobs, and O. Kayser, "Nanosuspensions as Particulate Drug Formulations in Therapy: Rationale for Development and What We Can Expect for the Future," Adv. Drug Deliv. Rev. 47 (1), 3-19 (2001).
13. E.M. Liversidge, G.G. Liversidge, and E.R. Cooper, "Nanosizing: A Formulation Approach for Poorly Water-Soluble Compounds," Eur. J. Pharm. Sci. 18 (2), 113-120 (2003).
14. P.R. Lockman et al., "Nanoparticle Technology for Drug Delivery Across the Blood-Brain Barrier," Drug Dev. Ind. Pharm. 28 (1), 1-13 (2002).
15. B.E. Rabinow, "Nanosuspensions in Drug Delivery," Nat. Rev Drug Discov. 3 (9), 785-796 (2004).
16. V.B. Patravale, A.A. Date, and R.M. Kulkarni, "Nanosuspensions: A Promising Drug Delivery Strategy," J. Pharm. Pharmacol. 56 (7), 827-840 (2004).
17. K. Peters et al., "Preparation of Clofazimine Nanosuspensions for Intravenous Use and Evaluation of its Therapeutic Efficacy in Murine Mycobacterium avium Infection," J. Antimicrob Chemother. 45 (1), 77-83, (2000).
18. S.M. Moghimi, A.C. Hunter, and J.C. Murray, "Long Circulating and Target-Specific Nanoparticles: Theory to Practice," Pharmacol. Rev. 53 (2), 283-318, (2001).
19. G.J. Vergote et al., "An Oral Controlled Release Matrix Pellet Formulation Containing Nanocrystalline Ketoprofen," Int. J. Pharm. 219 (1-2), 81-87 (2001).
20. R. Pignatello et al., "Eudragit RS100 Nanosuspensions for the Ophthalmic Controlled Delivery of Ibuprofen," Eur. J. Pharm. Sci. 16 (1-2), 3-61 (2002).
21. J.E. Kipp, "The Role of Solid Nanoparticle Technology in the Parenteral Delivery of Poorly Water-Soluble Drugs," Int. J. Pharm. 284 (1-2), 109-122 (2004).
22. G.G. Liversidge et al., "Surface Modified Drug Nanoparticles," US Patent 5,145,684 (1992).
23. G.G. Liversidge and K.C. Cundy, "Particle Size Reduction for Improvement of Oral Bioavailability of Hydrophobie Drugs: I. Absolute Oral Bioavailability of Nanocrystalline Danazol in Beagle Dogs," Int. J. Pharm. 125 (1), 91-97 (1995).
24. G.G. Liversidge and P. Conzentino, "Drug Particle Size Reduction for Decreasing Gastric Irritancy and Enhancing Absorption of Naproxen in Rats," Int. J. Pharm. 125 (2), 309-313 (1995).
25. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper, "Nanosizing: A Formulation Approach for Poorly Water-Soluble Compounds," Eur. J. Pharm. Sci. 18 (2), 113-20, (2003).
26. E.M. Liversidge et al., "Formulation and Antitumor Activity Evaluation of Nanocrystalline Suspensions of Poorly Soluble Anticancer Drugs," Pharm. Res. 13 (2), 272-278 (1996).
27. R.H. Muller et al., "Pharmaceutical Nanosuspensions for Medicament Administration as Systems with Increased Saturation Solubility and Rate of Solution," US Patent 5,858,410 (1999).
28. R.H. Muller and K. Peters, "Nanosuspensions for the Formulation of Poorly Soluble Drugs: I. Preparation by a Size Reduction Technique," Int. J. Pharm. 160 (2), 229-237 (1998).
29. K.P. Krause and R.H. Muller, "Production and Characterization of Highly Concentrated Nanosuspensions by High Pressure Homogenization," Int. J. Pharm. 214 (1-2), 21-24 (2001).
30. C. Jacobs, O. Kayser, and R.H. Muller, "Nanosuspensions as a New Approach for the Formulation for the Poorly Soluble Drug Tarazepide," Inf. J. Pharm. 196 (2), 161-164 (2000).
31. R.H. Muller, B.H.L. Bohm, and M.J. Grau, "Nanosuspensions: A Formulation Approach for Poorly Soluble and Poorly Bioavailable Drugs," in Handbook of Pharmaceutical Controlled Release Technology, D.L. Wise, Ed. (Marcel Dekker Inc., New York, NY, 2000), pp. 345-357.
32. R.H. Muller, C. Jacobs, and O. Kayser, "Nanosuspension for the Formulation of Poorly Soluble Drugs," in Pharmaceutical Emulsion and Suspension, F. Neilloud and G. Marti-Mestres, Eds. (Marcel Dekker Inc., New York, NY, 2000), pp. 383-407.
33. N. Scholer et al., "Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis," Antimicrob. Agents. Chemother. 45 (6), 1771-1779 (2001).
34. O. Kayser et al., "Formulation of Amphotericin B as Nanosuspension for Oral Administration," Int. J. Pharm. 254 (1), 73-75 (2003).
35. J. Hecq et al., "Preparation and Characterization of Nanocrystals for Solubility and Dissolution Rate Enhancement of Nifedipine," Int. J. Pharm. 299 (1-2), 167-177 (2005).
36. M. Trotta et al., "Emulsions Containing Partially Water-Miscible Solvents for the Preparation of Drug Nanosuspensions," J. Controlled Release 76 (1-2), 119-128, (2001).
37. M. Trotta et al., "Preparation of Griseofulvin Nanoparticles from Aater-Dilutable Microemulsions," Int. J. Pharm. 254 (2), 235-242 (2003).
38. D.J. Dixon, K.P. Johnston, and R.A. Brodemier, "Polymeric Materials Formed by Precipitation with a Compressed Fluid Antisolvent," AIChE J. 39 (1), 127-139 (1993).
39. E. Reverchon and G.D. Porta, "Production of Antibiotic Micro- and Nano-Particles by Supercritical Antisolvent Precipitation," Powder Technol 106 (1-2), 23-29, (1999).
40. P. Chattopadhyay and R.B. Gupta, "Protein Nanoparticles Formation by Supercritical Antisolvent with Enhanced Mass Transfer," AIChE J. 48, 235-244 (2002).
41. M.H. Hanna and P. York, "Method & Apparatus for the Formation of Particles," US Patent, 5,851,453 (1998).
42. B. Subramaniam et al., "Methods for a Particle Precipitation and Coating Using Near-Critical and Supercritical Antisolvents," US Patent 5,833,891 (1997).
43. T.J. Young et al., "Encapsulation of Lysozyme in a Biodegradable Polymer by Precipitation with a Vapor-Over-Liquid Antisolvent," J. Pharm. Sci. 88 (6), 640-650 (2000).
44. M. Turk et al., "Micronization of Pharmaceutical Substances by the Rapid Expansion of Supercritical Solutions (RESS): A Promising Method to Improve Bioavailability of Poorly Soluble Pharmaceutical Agents," J. Supercrit. Fluids 22 (1), 75-84 (2002).
45. T.J. Young et al., "Rapid Expansion from Supercritical to Aqueous Solution to Produce Submicron Suspensions of Water-Insoluble Drugs," Biotechnol. Prog. 16 (3), 402-407 (2000).
46. G.W. Pace et al., "Processes to Generate Submicron Particles of Water-Insoluble Compounds," US Patent 6,177,103 (2001).
47. R.O. Williams et al., "Process for Production of Nanoparticles and Microparticles by Spray Freezing in to Liquid," US Patent 6,862,890 (2005).
48. T.L. Rogers et al., "A Novel Particle Engineering Technology: Spray Freezing in to Liquid," Int. J. Pharm. 242 (1-2), 93-100 (2002).
49. T.L. Rogers et al., "A Novel Particle Engineering Technology to Enhance Dissolution of Poorly Water Soluble Drugs: Spray Freezing into Liquid," Eur. J. Pharm. BioPharm. 54 (3), 271-280 (2002).
50. T.L. Rogers et al., "Enhanced Aqueous Dissolution of a Poorly Water-Soluble Drug by Novel Particle Engineering Technology: Spray Freezing in to Liquid with Atmospheric Freeze-Drying," Pharm. Res. 20 (3), 485-493 (2003).
51. J. Hu, K.P. Johnston, and R.O. Williams, "Spray Freezing into Liquid (SFL) Particle Engineering Technology to Enhance Dissolution of Poorly Water Soluble Drugs: Organic Solvent vs. Aqueous-Organic Co-solvent Systems," Eur. J. Pharm. Sci. 20 (3), 295-303 (2003).
52. J. Hu, K.P. Johnston, and R.O. Williams III, "Rapid Dissolving High Potency Danazol Powders Produced by Spray Freezing into Liquid Process," Int. J. Pharm. 271 (1-2), 145-154 (2004).
53. J. Hu, K.P. Johnston, and R.O. Williams III, "Stable Amorphous Danazol Nanostructured Powders with Rapid Dissolution Rates Produced by Spray Freezing into Liquid," Drug Dev. Ind. Pharm. 30 (7), 695-704 (2004).
54. X. Chen et al., "Preparation of Cyclosporine A Nanoparticles by Evaporative Precipitation into Aqueous Solution," Int. J. Pharm. 242 (1-2), 3-14 (2002).
55. M. Sarkari et al., "Enhanced Drug Dissolution Using Evaporative Precipitation into Aqueous Solution," Int. J. Pharm. 243 (1-2), 17-31 (2002).
56. X. Chen, R.O. Williams, and K.P. Johnston, "Rapid Dissolution of High Potency Danazol Powders Produced by Evaporative Precipitation into Aqueous Solution," J. Pharm. Sci. 93 (7), 1867-1878 (2004).
57. J.M. Vaughn et al., "Comparison of Powder Produced by Evaporative Precipitation into Aqueous Solution (EPAS) and Spray Freezing into Liquid (SFL) Technologies Using Novel Z-contrast STEM and Complimentary Techniques," Eur. J. Pharm. Biopharm. 60 (1), 81-89 (2005).
58. J.E. Kipps et al., "Microprecipitation Method for Preparing Submicron Suspensions," US Patent 6,607,784 (2003).
59. O.V. Kozyuk, "Device and Method for Creating Hydrodynamic Cavitation in Fluids," US Patent 6,502,979 (2003).